SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a massive parabolic rally driven by an extremely low float, intense short-squeeze dynamics, and significant speculation regarding its pivot from cannabis to telecommunications infrastructure in Mexico. The community is heavily focused on the high cost-to-borrow rates and the potential for a continued squeeze, leading to heated debates between bullish traders capitalizing on the momentum and skeptical observers warning of potential dilution and volatility.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened market scrutiny ahead of its earnings report as investors debate the impact of significant capital expenditure and dilution risks against the potential growth catalyst of the R2 platform. While some community members remain optimistic about long-term production scaling and the company's strategic partnerships, others are concerned about cash burn, share dilution, and executive compensation packages amidst a volatile electric vehicle market.

The White Alien has arrived. The countdown to domination starts now.

The White Alien

The White Alien is generating buzz through aggressive social media cross-promotion with various other memecoins, sparking intense community debate between optimistic traders betting on rapid price momentum and skeptics questioning the token's long-term legitimacy.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently surging on the strength of back-to-back mission successes and an aggressive launch cadence, with the community closely tracking its growing role in defense contracts and space infrastructure. Investors are highly optimistic about the stock's potential for triple-digit growth, driven by institutional confidence, anticipation of upcoming earnings, and the company's status as a key infrastructure player alongside SpaceX.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing extreme volatility and heavy volume as traders react to a recent preclinical milestone payment and an upcoming R&D presentation, while others express deep skepticism regarding the company's long-term performance and potential reverse split. The community is sharply divided, with bulls pointing to fundamental technology developments and Big Pharma partnerships, while bears highlight persistent dilution, management concerns, and a downward trend in share price.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is seeing heightened volatility and intense social media debate after a sharp decline in share price triggered concerns regarding slowing user engagement and long-term monetization. The community is deeply divided between long-term investors highlighting strong free cash flow and persistent growth, and vocal critics pointing to unresolved safety concerns and a challenging regulatory environment for youth-oriented platforms.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending as investors debate whether the stock represents a deep-value opportunity following its recent reorganization into three standalone business units, including a separate segment for Venmo. While some market participants are optimistic that these structural changes and potential strategic flexibility will unlock significant shareholder value, others remain skeptical, pointing to persistent competitive pressures and the stock's long-term underperformance.

Alchemy Pay

Alchemy Pay is capturing significant community attention as investors debate its transition toward a Layer 1 blockchain and expansion of its fiat-to-crypto payment infrastructure. While some traders are bullish on new regulatory licensing and upcoming mainnet developments, others are actively debating concerns regarding token supply inflation and the project's long-term competitive moat against other payment solutions.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing heightened market attention driven by its strategic role in domestic critical mineral supply chains, with community discourse heavily focused on government defense contracts and the impact of ongoing geopolitical trade restrictions. Investors are actively debating the timing of potential catalysts, with many closely monitoring technical chart patterns and volume spikes as indicators of a possible sustained trend or short-term breakout.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating renewed buzz as the community closely watches critical resistance levels, with many speculating that a breakout could trigger a significant upward trend. Investors are actively debating the token's potential to lead a broader crypto rally, balancing optimism regarding its long-term utility against frustrations over recent price consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Momentum across psychedelic stocks gained after Trump signed an exec order directing the FDA to accelerate review of psychedelic therapies and committed $50 million towards research.</li><li>The company said it holds standardized, stabilized GMP-compliant ibogaine doses in inventory in a market where access to clinical-grade material remains limited.</li><li>Through its investment in PsyLabs, Psyence has built a vertically integrated platform spanning sourcing in Africa through extraction, purification and pharma production.</li></ul>Shares of Psyence Biomedical (PBM) surged into the spotlight again on Monday after the company underscored its pharma-grade ibogaine inventory advantage just as a new White House order boosted momentum behind psychedelic medicine research.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has logged a three-day winning streak, gaining 182% over the same period.&nbsp;<h2 class="st-heading-2">PBM Targets Global Ibogaine Supply Gap</h2>Psyence Biomedical said on Monday that it currently holds standardized, stabilized and Good Manufacturing Practice (GMP)-compliant ibogaine doses in inventory in a market where access to pharma-grade material remains limited and fragmented.Through its investment in PsyLabs, the company has built an integrated platform spanning sourcing at origin in Africa through extraction, purification and pharmaceutical production.&nbsp;“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” CEO Jody Aufrichtig said. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”The company added that its vertically integrated platform can reduce delays tied in supply constraints that have historically slowed progress in ibogaine-based clinical research.<h2 class="st-heading-2">PBM Rides FDA Psychedelic Review Momentum</h2>The supply update comes shortly after U.S. President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite review of psychedelic medicines, including ibogaine, while committing $50 million in funding toward related clinical-research programs.At the Oval Office signing ceremony, Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence, particularly for veterans with serious mental-health conditions.&nbsp;Ibogaine, a compound derived from a Central and West African shrub, remains classified as a Schedule I substance in the U.S. but has attracted growing attention for its potential role in treating post-traumatic stress disorder.The policy move triggered a broad rally across psychedelic-therapy developers. Shares of Enveric Biosciences (ENVB) surged 101%, Compass Pathways (CMPS) jumped 42%, Atai Life Sciences (ATAI) gained 22%, and Definium Therapeutics (DFTX) rose 2% on Monday.<h2 class="st-heading-2">PBM Builds Ibogaine Supply From Africa&nbsp;</h2>Operating near ibogaine’s natural source in Central and West Africa, PsyLabs has secured direct access to raw material with in-region processing to support traceable, reliable, and ethically sourced supply.&nbsp;Earlier this year, Psyence said it produced high-purity ibogaine hydrochloride from ethically sourced iboga bark and exported a GMP-compliant psilocybin product, NPX-5, to Australia for a Phase IIb trial in adjustment disorder among patients receiving palliative cancer care.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM was ‘extremely bullish’ amid an eye-watering 82,550% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_36a8236907.webp" alt="pbm ss.png" width="967" height="133"><figcaption>TSLA sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LowDownDog12/message/650809854">said</a>, “Still holding my 5200 shares at 2.40. Bought believing this company could be the first to get ibogaine to market and still do.”<stembedurl>https://stocktwits.com/LowDownDog12/message/650809854</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/livetotradestox/message/650823742">noted</a> PBM's description of itself as the world’s only licensed pharma-grade ibogaine supplier at source level, and said: "Only sounds like a monopoly. At the very least a moat because of high barriers to entry for competitors."<stembedurl>https://stocktwits.com/livetotradestox/message/650823742</stembedurl>The stock has declined 48% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-founder-bull-case-anktiva-breast-cancer-signal/cZBIIqmRICd">IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push

PBM stock extended its rally to a three-day winning streak, gaining about 182% over the period as investors focused on supply benefits in the ibogaine ecosystem.

Equity

From Concrete to Consciousness: Wall Street Chases QXO $17B Megadeal and Psychedelic Moonshots

The week’s first power hour includes a powerful cross-sector narrative: hard assets meet high-concept science. On one side, a massive consolidation in construction materials signals long-term conviction in infrastructure and development. On the other, a cluster of small- and mid-cap biotech names, many tied to next-generation mental health treatments, are catching momentum simultaneously. $PBM, $QXO, $BLD, $XERI, $TOVX, $POET, $SLNH, $ATAI, $PBM, $CMPS

AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump FastTrack Order

AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.read more...

AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating

<ul class="summary-bullets"><li>Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.</li><li>Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.</li><li>Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.</li></ul> Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.<h2 class="st-heading-2">Wall Street Boost</h2>Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.<stembedurl>https://www.stocktwits.com/twiggs462/message/650773904</stembedurl>Another user cheered Atai’s great assets and voiced hopes for further rallies in future.<stembedurl>https://www.stocktwits.com/brunoq14/message/650772195</stembedurl><a href="https://stocktwits.com/symbol/ATAI">ATAI stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/agio-stock-slumps-whats-the-novo-connection/cZBd0tMRIzi">AGIO Stock Slumps 25% – What’s The Novo Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, spurring a rally among psychedelic drug developer stocks. 

<ul class="summary-bullets"><li>The order calls on the FDA to give priority to select psychedelic treatments that have demonstrated positive results in preliminary research.&nbsp;</li><li>The treatments could qualify for priority review, enabling regulators to assess them faster while upholding safety requirements.</li><li>COMP360, Compass’s psilocybin therapy in late-stage trials, has shown relief within a day, with effects lasting up to six months after one or two doses.&nbsp;</li></ul>Compass Pathways (CMPS) stock gained overnight on Sunday as the company voiced support for the White House’s executive action to speed up research, approval, and availability of psychedelic-based treatments.The company specializes in psilocybin therapies, which stand to benefit from faster regulatory timelines tied to its lead candidate.&nbsp;<h2 class="st-heading-2">Regulatory Changes To Speed Access</h2>President Donald Trump on Saturday signed the order to speed up the development, review, and accessibility of treatments targeting complex psychiatric conditions. The policy outlines a coordinated effort across federal agencies to reduce regulatory delays and expand research opportunities. The order instructs the Food and Drug Administration (FDA) to prioritize certain psychedelic drugs that have already shown promise in early studies.&nbsp;These therapies may receive special review vouchers, allowing regulators to evaluate them more quickly without compromising safety standards. In parallel, the FDA and the Drug Enforcement Administration are tasked with designing pathways that permit eligible patients to access investigational treatments still under review, provided they meet baseline safety criteria.<h2 class="st-heading-2">Compass Lead Candidate Gains Momentum</h2>Compass said it is already engaged in ongoing review discussions with the FDA, positioning it to capitalize on the policy shift as it advances treatment for depression.<blockquote>“Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin,” said CEO Kabir Nath.</blockquote>At the center of this development is COMP360, the company’s synthetic psilocybin therapy currently in late-stage trials. Phase 3 trial findings suggest the treatment may produce rapid improvements, with patients experiencing relief within a day and sustained benefits lasting about six months after just 1 or 2 doses.<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways’ stock</a> was up over 2%&nbsp;as of its last after-hours close. Peers&nbsp;Enveric Biosciences and ATAI Life Sciences were up over 3.5% and 1.1%, respectively.&nbsp;The company’s study includes data from more than 1,000 participants, indicating a generally manageable safety profile with short-lived side effects. Beyond depression, Compass is expanding its focus to PTSD, including collaboration with Veterans Affairs programs to explore treatment options.<h2 class="st-heading-2">What Are Retail Traders Saying?&nbsp;</h2>On Stocktwits, retail sentiment for Compass Pathways remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels,&nbsp;which have surged by 2,000% over the past seven days.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_19_214919_png_16ee490f83.webp" alt="CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits" width="930" height="97"><figcaption>CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user&nbsp;<a href="https://stocktwits.com/Canvasback33/message/650726549">expressed</a> optimism about COMP360 receiving approval and availability.&nbsp;“EO [executive order] was the last hurdle in my mind for this stock. Federal govt has cleared the run way for psychedelic medicine and the FDA is on board. I truly believe this will be approved and is going to market. This is the future of mental health.”<stembedurl>https://stocktwits.com/Canvasback33/message/650726549</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Millionaire11/message/650726940">said</a>:&nbsp;“This is not a sell the news event. This news was not expected. This will skyrocket upon FDA approval anticipation. Once FDA approved, I could see a sell the news event but for now enjoy the gains this week.”<stembedurl>https://stocktwits.com/Millionaire11/message/650726940</stembedurl>CMPS stock has declined over 3% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-china-surge-shows-pricing-power-matters-in-a-supply-crunch-retail-bulls-take-notice/cZJUsxBRIUG">Apple’s China Surge Shows Pricing Power Matters In A Supply Crunch – Retail Bulls Take Notice</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

CMPS Stock Surges As White House Psychedelic Push Prompts FDA Review, Boosts COMP360 Prospects

CMPS Stock - On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 

CMPS Stock Jumps Overnight After Trump Order Fast-Tracks Psychedelic Therapies

On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 


<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

New Strong Sell Stocks for Jan. 13

ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

Current Price	$4.16
Prev Close	$4.12
Open	$4.12
Dividend Yield	0.00%
50-Day Moving Average	$3.88
Beta	1.49
Avg. Volume	5.38M
PE Ratio	-1.80

52-Week High	$6.75
52-Week Low	$1.29
Market Capitalization	$1.51B
EPS (Annual)	-$2.91
Price to Book	6.81
Revenue Per Employee	$34,948.72

ATAI
AtaiBeckley Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest ATAI News

ATAIAtaiBeckley Inc.